Abstract
Purpose. To identify more accurately in the spleen, the areas and the cells where nanoparticulate carriers were taken up from the blood flow, a series of complementary approaches were used.
Methods. First,in and ex vivo examination of the whole spleen led to a global view of all the trapping areas. Then, histological studies on frozen sections of the same organ allowed for a more precise localization of these areas and image analysis gave an evaluation of tissue distribution of the nanoparticles. Finally, immunological and enzymological characteristics of the capturing cells were determined in situ, using monoclonal antibodies (F4/80 and anti-sialoadhesin) and cyto-chemichal reactions (esterases and acid phosphatase). Furthermore incubation of spleen slices with different nanoparticles was used so as to know if the capture was due to a high capturing capacity of these cells or to a high blood flow in their vicinity.
Results. It was shown that more than 90% of the splenic capture was localized in the marginal zone of the follicles. The capturing cells form a special population of macrophages inserted in a reticular meshwork, showing low esterase and acid phosphatase activities, giving faint or no reaction with F4/80 or anti-sialoadhesin antibodies. The circulating nanoparticles were quickly trapped with rather low specificity by these cells.
Conclusions. Combination of coherent approaches allowed for the tracking of capturing cells from in vivo observations to their in situ identification on immunological and enzymological criteria.
Similar content being viewed by others
REFERENCES
C. Verdun, F. Brasseur, H. Vranckx, P. Couvreur, and M. Roland. Cancer Chemother. Pharmacol. 26:13–18 (1990).
I. C. Mac Donald, D. M. Ragan, E. E. Schmidt, and A. C. Groom. Microvascular Res. 42:60–76 (1991).
G. Flandrin and M. Th. Daniel. Path. Biol. 19:9–10, 547–555 (1974).
C. Y. Li, L. T. Yam, and K. W. Lam. J. Histochem. Cytochem. 18:901 (1970).
C. D. Dijkstra, E. Van Vliet, E. A. Döpp, A. A. Van Der Lelij, and G. Kraal. Immunology. 55:23–30 (1985).
J. H. Humphrey and D. Grennan. Eur. J. Immunol. 11:221–228 (1981).
L. Grislain, P. Couvreur, V. Lenaerts, M. Roland, D. Deprez-Decampaneere, and P. Speiser. Int. J. Pharm. 15:335–345 (1983).
L. Illum and S. S. Davis. FEBS Lett. 167(1):79–82 (1984).
L. Illum, S. S. Davis, R. H. Müller, E. Mak, and P. West. Life Sci. (1987), 40:367–374 (1987).
J. E. O'Mullane, K. Petrak, L. E. F. Hutchinson, and E. Tomlinson. Int. J. Pharm. 63:177–180 (1990).
G. Kraal. Int. Rev. Cytol. Academic Press. Inc. 1992, pp. 31–74.
C. J. Porter, M. C. Davies., S. S. Davis, and L. Illum. Polymeric Site Specific Pharmacotherapy. A. J. Domb, John Wiley & Son Ltd, 1994, pp. 57–203.
S. M. Moghimi, C. J. Porter, I. S. Muir, L. Illum, and S. S. Davis. Biochem. Biophys. Res. Commun. 177(2):861–866 (1991).
G. Storm G., S. O. Belliot, T. Daemen, and D. D. Lasic. Adv. Drug Deliv. Rev. 17:31–48 (1995).
T. Snook. Am. J. Anat. 87:31–61 (1950).
A. C. Groom, E. E. Schmidt, and I. C. Mac Donald. Scanning Microscopy 5:159–174 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Demoy, M., Gibaud, S., Andreux, J.P. et al. Splenic Trapping of Nanoparticles: Complementary Approaches for In Situ Studies. Pharm Res 14, 463–468 (1997). https://doi.org/10.1023/A:1012095431931
Issue Date:
DOI: https://doi.org/10.1023/A:1012095431931